Payment overview · 2025
General Payments
$729.28
38 reported records · 15 companies
Healthcare provider profile · identity verified
Michael R Black, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · PROCTORVILLE, OH · NPI 1588892194
Verified facts
What the public records show
CMS Open Payments records show Michael R Black, M.D. received $729.28 in general payments during 2025 across 38 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 23.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Kerendia, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Kerendia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $174.49 | 23.9% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $91.16 | 12.5% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $78.45 | 10.8% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $73.43 | 10.1% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $47.83 | 6.6% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $44.16 | 6.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $33.65 | 4.6% | 2 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.64 | 4.6% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $31.92 | 4.4% | 2 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $25.24 | 3.5% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $23.30 | 3.2% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $21.59 | 3.0% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $21.10 | 2.9% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $18.18 | 2.5% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $11.14 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $729.28 | 38 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $174.49 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $73.43 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $73.43 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $59.38 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $44.16 | 2 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $33.64 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $31.92 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $31.78 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $31.18 | 2 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $25.24 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $23.30 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $21.59 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $21.40 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $21.10 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $18.18 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $17.68 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $17.68 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $17.68 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.42 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.65 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.65 | 1 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $16.26 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.97 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.67 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.67 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $11.14 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 122 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 90 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 143 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
101 | 17 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
122 | 37 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
90 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
61 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
143 | 28 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
155 | 34 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
17 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 594 | 174 |
| Gabapentin | Gabapentin | 535 | 102 |
| Omeprazole | Omeprazole | 475 | 123 |
| Levothyroxine Sodium | Levothyroxine Sodium | 456 | 113 |
| Lisinopril | Lisinopril | 439 | 126 |
| Losartan Potassium | Losartan Potassium | 431 | 107 |
| Amlodipine Besylate | Amlodipine Besylate | 351 | 94 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 299 | 76 |
| Metoprolol Succinate | Metoprolol Succinate | 284 | 78 |
| Hydrochlorothiazide | Hydrochlorothiazide | 272 | 70 |
| Sertraline Hcl | Sertraline Hcl | 253 | 68 |
| Furosemide | Furosemide | 243 | 75 |
| Metformin Hcl | Metformin Hcl | 236 | 67 |
| Fluticasone Propionate | Fluticasone Propionate | 216 | 70 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 211 | 58 |
| Buspirone Hcl | Buspirone Hcl | 210 | 52 |
| Pantoprazole Sodium | Pantoprazole Sodium | 208 | 62 |
| Duloxetine Hcl | Duloxetine Hcl | 204 | 42 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 199 | 47 |
| Tizanidine Hcl | Tizanidine Hcl | 199 | 54 |
| Tramadol Hcl | Tramadol Hcl | 190 | 38 |
| Potassium Chloride | Potassium Chloride | 182 | 53 |
| Zolpidem Tartrate | Zolpidem Tartrate | 167 | 25 |
| Ibuprofen | Ibuprofen | 159 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 157 | 43 |
| Eliquis | Apixaban | 155 | 34 |
| Simvastatin | Simvastatin | 148 | 41 |
| Trazodone Hcl | Trazodone Hcl | 145 | 45 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 143 | 36 |
| Ozempic | Semaglutide | 143 | 28 |
| Prednisone | Prednisone | 143 | 83 |
| Montelukast Sodium | Montelukast Sodium | 142 | 38 |
| Meloxicam | Meloxicam | 138 | 32 |
| Famotidine | Famotidine | 136 | 39 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 132 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 130 | 33 |
| Carvedilol | Carvedilol | 124 | 32 |
| Jardiance | Empagliflozin | 122 | 37 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 120 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 118 | 31 |
| Glipizide | Glipizide | 111 | 33 |
| Alprazolam | Alprazolam | 108 | 22 |
| Amitriptyline Hcl | Amitriptyline Hcl | 108 | 24 |
| Ventolin Hfa | Albuterol Sulfate | 108 | 27 |
| Ropinirole Hcl | Ropinirole Hcl | 105 | 22 |
| Pregabalin | Pregabalin | 102 | 35 |
| Symbicort | Budesonide/Formoterol Fumarate | 101 | 17 |
| Metformin Hcl Er | Metformin Hcl | 93 | 23 |
| Allopurinol | Allopurinol | 92 | 20 |
| Spiriva Respimat | Tiotropium Bromide | 91 | 23 |
| Bupropion Xl | Bupropion Hcl | 90 | 27 |
| Mounjaro | Tirzepatide | 90 | 16 |
| Warfarin Sodium | Warfarin Sodium | 86 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 84 | 24 |
| Ondansetron Hcl | Ondansetron Hcl | 84 | 32 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 84 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 77 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 75 | 22 |
| Alendronate Sodium | Alendronate Sodium | 74 | 18 |
| Clonazepam | Clonazepam | 74 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 72 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 70 | 18 |
| Glimepiride | Glimepiride | 67 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 66 | 19 |
| Methocarbamol | Methocarbamol | 65 | 21 |
| Doxycycline Hyclate | Doxycycline Hyclate | 64 | 41 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 64 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 64 | 18 |
| Promethazine Hcl | Promethazine Hcl | 63 | suppressed |
| Lorazepam | Lorazepam | 62 | 13 |
| Trulicity | Dulaglutide | 61 | suppressed |
| Januvia | Sitagliptin Phosphate | 59 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 58 | 18 |
| Nystatin | Nystatin | 55 | 23 |
| Nifedipine Er | Nifedipine | 52 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 52 | 34 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 50 | suppressed |
| Spironolactone | Spironolactone | 49 | 16 |
| Celecoxib | Celecoxib | 48 | 12 |
| Fluconazole | Fluconazole | 47 | 18 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 45 | 15 |
| Atenolol | Atenolol | 44 | 17 |
| Donepezil Hcl | Donepezil Hcl | 44 | 11 |
| Cephalexin | Cephalexin | 43 | 33 |
| Fenofibrate | Fenofibrate | 43 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 41 | suppressed |
| Ezetimibe | Ezetimibe | 40 | suppressed |
| Novolog Flexpen | Insulin Aspart | 39 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 39 | 11 |
| Linzess | Linaclotide | 38 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 38 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 37 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 37 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 37 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 36 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 36 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | 22 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 36 | 15 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 35 | 14 |
| Glipizide Er | Glipizide | 34 | suppressed |
| Xarelto | Rivaroxaban | 33 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 32 | suppressed |
| Diazepam | Diazepam | 31 | suppressed |
| Synthroid | Levothyroxine Sodium | 31 | suppressed |
| Azithromycin | Azithromycin | 29 | 25 |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | 11 |
| Meclizine Hcl | Meclizine Hcl | 29 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Baclofen | Baclofen | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 26 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Finasteride | Finasteride | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Klor-Con M20 | Potassium Chloride | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 22 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 15 |
| Spiriva Handihaler | Tiotropium Bromide | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Acyclovir | Acyclovir | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 19 |
| Colchicine | Colchicine | 20 | suppressed |
| Vraylar | Cariprazine Hcl | 20 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 16 |
| Sucralfate | Sucralfate | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 12 |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 16 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Kerendia | Finerenone | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 11 |
| Estradiol | Estradiol | 14 | suppressed |
| Ibu | Ibuprofen | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Cefdinir | Cefdinir | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 12 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Fluocinolone Acetonide Oil | Fluocinolone Acetonide Oil | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $729.28 · 38 records | Bayer Healthcare Pharmaceuticals Inc. | ABRYSVO, AIRSUPRA, BREZTRI, CAPLYTA, COMIRNATY, GEMTESA, JARDIANCE, Kerendia, MOUNJARO, NURTEC ODT, NUZYRA, OTEZLA, Ohtuvayre, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, Sunosi, TONMYA, UBRELVY, Veozah, Wegovy, XHANCE, XIFAXAN, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error